Answers are grounded in this paper and cite their sources.
Polypharmacy in the treatment of bipolar disorder is the rule rather than the exception. This has been documented in numerous studies carried out in many countries. Some studies indicate that polypharmacy may be more effective than monotherapy in the prophylaxis of BD. Considering the complex neurobiological basis of BD and the ever-better-known mechanisms of action of mood stabilizers (MS) and second-generation antipsychotics (SGA), one can suppose that in the future the neurobiological signature will allow for the administration of drugs that will cover all disturbed underlying processes. This review presents data showing that individualized approach to the prophylactic treatment of bipolar patients based on their specific neurobiological profile and better knowledge on the effects of the use of two or more mood stabilizing drugs may significantly improve the efficacy of the treatment.
No takes yet. Share an insight, caveat, or question.
Jaracz et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: